YD Bio Limited
As of Oct 22, 2026, YD Bio is in Stage 1, the basing phase, now in week 8 (since Aug 31, 2026). It closed at $4.24, 75.9% below its 52-week high and below its 200-day average, which is falling.
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is YDES early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
YDES among Biotechnology464th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …464 | YDES | Stage 1 · wk 8 | 12 | +31.3% |
YD Bio: quick answers
What stage is YD Bio in?
As of Oct 22, 2026, YD Bio (YDES) is in Stage 1, the basing phase. It entered Stage 1 on Aug 31, 2026 and is in week 8. What the four stages mean
Is YD Bio in an uptrend?
Not yet. YD Bio is in Stage 1, a base that can come before an uptrend. It trades 25.7% below its 200-day average, which is falling.
How far is YD Bio from its 52-week high?
YD Bio closed at $4.24 on Oct 22, 2026, 75.9% below its 52-week high of $17.61. Its 52-week low is $1.90.
How has YD Bio performed over the past year?
As of Oct 22, 2026, YD Bio is down 77.1% over the past year and down 64.7% so far in 2026.
Which sector and industry is YD Bio in?
YD Bio is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.